Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vanda Pharmaceuticals Inc.    VNDA

VANDA PHARMACEUTICALS INC. (VNDA)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Vanda Pharmaceuticals : Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:14pm CEST

WASHINGTON, Nov. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum™ (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. In July 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the Fanaptum™ MAA. Vanda requested a re-examination of the initial opinion. After considering the grounds for this request, the CHMP re-examined the opinion and confirmed the refusal of the Fanaptum™ MAA on November 9, 2017.

About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

About Fanapt

For full U.S. Prescribing Information for Fanapt, including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

View original content:http://www.prnewswire.com/news-releases/vanda-receives-negative-opinion-for-marketing-authorization-from-the-european-medicines-agency-on-fanaptum-for-the-treatment-of-schizophrenia-300554039.html

SOURCE Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. published this content on 10 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 November 2017 21:13:01 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VANDA PHARMACEUTICALS INC.
09/20VANDA PHARMACEUTICALS : Announces Listing of a New HETLIOZ® Patent in the FDA Or..
PR
09/20VANDA PHARMACEUTICALS : HETLIOZ® Tasimelteon Driving Study Demonstrates No Impai..
AQ
09/20VANDA PHARMACEUTICALS : Patent Issued for Highly Purifid Pharmaceutical Grade Ta..
AQ
09/14VANDA PHARMACEUTICALS INC. : - HETLIOZ Driving Study Demonstrates No Impairment ..
AQ
09/13VANDA PHARMACEUTICALS : Patent Application Titled "Melatonin Agonist Treatment" ..
AQ
09/13VANDA PHARMACEUTICALS : HETLIOZ® (Tasimelteon) Driving Study Demonstrates No Imp..
PR
09/06VANDA PHARMACEUTICALS : Researchers Submit Patent Application, "Method Of Predic..
AQ
09/04VANDA PHARMACEUTICALS : Announces Participation at September 2018 Investor Confe..
PR
08/14VANDA PHARMACEUTICALS INC. : Other Events, Financial Statements and Exhibits (fo..
AQ
08/14VANDA PHARMACEUTICALS : Wins Denial of Petition For Rehearing on Fanapt®
PR
More news
News from SeekingAlpha
09/21Vanda announces listing of a new HETLIOZ patent in the FDA orange book 
09/17VANDA : A Grower Operating At An Inflection 
09/13Vanda Pharmaceuticals +1.1% as Stifel starts at Buy 
09/13HETLIOZ driving study demonstrates no impairment in next morning performance 
08/28BY THE NUMBERS : Growth Leaders With Strong Momentum 
Financials ($)
Sales 2018 193 M
EBIT 2018 0,40 M
Net income 2018 1,03 M
Finance 2018 4,50 M
Yield 2018 -
P/E ratio 2018 409,00
P/E ratio 2019 44,65
Capi. / Sales 2018 5,53x
Capi. / Sales 2019 4,41x
Capitalization 1 071 M
Chart VANDA PHARMACEUTICALS INC.
Duration : Period :
Vanda Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VANDA PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 23,7 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Mihael Hristos Polymeropoulos President, Chief Executive Officer & Director
H. Thomas Watkins Chairman
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
Vincent J. Milano Independent Director
Michael F. Cola Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VANDA PHARMACEUTICALS INC.34.54%1 071
GILEAD SCIENCES5.56%98 029
VERTEX PHARMACEUTICALS21.56%46 555
REGENERON PHARMACEUTICALS3.81%41 417
NEUROCRINE BIOSCIENCES, INC.56.01%10 951
SAREPTA THERAPEUTICS INC165.26%10 172